Bharat Biotech announced that its typhoid vaccine Typbar TCV has received World Health Organization pre-qualification, as reported Business Standard Wednesday.
The approval follows a positive recommendation by WHO's Strategic Advisory Group of Experts on Immunisation.
"Typbar TCV is the first typhoid vaccine, clinically proven to be administered to children from six months of age to adults and confers long-term protection against typhoid fever," Bharat stated.
"The WHO pre-qualification of Typbar TCV marks an important milestone in the global effort to rid the world of typhoid fever and improve health for some of the most vulnerable populations in the world," commented Oxford University professor Andrew Pollard.
To read more NewsPoints articles, click here.